Westpac Banking Corp trimmed its position in DaVita Inc. (NYSE:DVA – Free Report) by 33.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,982 shares of the company’s stock after selling 5,585 shares during the quarter. Westpac Banking Corp’s holdings in DaVita were worth $891,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of DVA. Sentry Investment Management LLC lifted its holdings in shares of DaVita by 63.4% in the fourth quarter. Sentry Investment Management LLC now owns 371 shares of the company’s stock worth $28,000 after buying an additional 144 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock valued at $35,000 after purchasing an additional 147 shares in the last quarter. CWM LLC raised its stake in DaVita by 78.1% in the first quarter. CWM LLC now owns 830 shares of the company’s stock valued at $67,000 after purchasing an additional 364 shares in the last quarter. OLD Mission Capital LLC purchased a new stake in DaVita in the fourth quarter valued at approximately $76,000. Finally, CoreCap Advisors LLC purchased a new stake in DaVita in the fourth quarter valued at approximately $107,000. 83.78% of the stock is owned by hedge funds and other institutional investors.
DaVita Stock Down 0.4 %
Shares of DaVita stock opened at $101.97 on Thursday. The company has a debt-to-equity ratio of 8.25, a quick ratio of 1.14 and a current ratio of 1.18. DaVita Inc. has a 52-week low of $65.28 and a 52-week high of $106.96. The stock has a market capitalization of $9.25 billion, a price-to-earnings ratio of 18.81, a P/E/G ratio of 1.05 and a beta of 0.94. The company’s 50 day moving average price is $99.83 and its 200-day moving average price is $89.61.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on DVA shares. StockNews.com started coverage on shares of DaVita in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. UBS Group raised their target price on shares of DaVita from $91.00 to $100.00 in a research note on Tuesday, May 9th. Truist Financial increased their price target on shares of DaVita from $100.00 to $115.00 and gave the company a “hold” rating in a research report on Thursday, July 13th. Deutsche Bank Aktiengesellschaft increased their price target on shares of DaVita from $85.00 to $113.00 in a research report on Tuesday, May 9th. Finally, Sanford C. Bernstein increased their price target on shares of DaVita from $88.00 to $100.00 in a research report on Monday, May 15th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $98.75.
Insider Transactions at DaVita
In related news, Director Phyllis R. Yale sold 2,196 shares of DaVita stock in a transaction on Friday, May 12th. The shares were sold at an average price of $95.26, for a total value of $209,190.96. Following the sale, the director now owns 13,110 shares in the company, valued at $1,248,858.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Barbara J. Desoer sold 2,449 shares of DaVita stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $101.61, for a total value of $248,842.89. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Phyllis R. Yale sold 2,196 shares of DaVita stock in a transaction on Friday, May 12th. The shares were sold at an average price of $95.26, for a total transaction of $209,190.96. Following the completion of the sale, the director now owns 13,110 shares in the company, valued at approximately $1,248,858.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,502 shares of company stock worth $3,722,146. Insiders own 1.40% of the company’s stock.
About DaVita
DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
Further Reading
- Five stocks we like better than DaVita
- How to Invest in Growth Stocks
- 5 Best Office REITs to Buy Now
- Investing in Travel Stocks Benefits
- Camping World Slashes its Dividend but Should You Cut the Stock?
- Best Restaurant Stocks to Invest in Now
- SoFi Downgraded: Here’s How To Still Make Money
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
